Solid Tumor Targeting CAR-T Development Service with ADCC Switch

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

CAR-T therapy faces significant safety challenges, including severe adverse effects such as "on-target, off-tumor" toxicity due to recognition of normal tissues and cytokine release syndrome (CRS), highlighting the urgent need for efficient and controllable safety switch systems to enable precise regulation. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with ADCC Switch co-expresses targetable surface markers, such as EGFRt and its optimized variant EGFRopt, allowing rapid and specific ablation of CAR-T cells when necessary to effectively mitigate treatment-related toxicities. Our service is distinguished by the use of engineered high-expression safety switches, which significantly enhance antibody-mediated clearance efficiency.

Introduction

The ADCC switch is a safety control mechanism based on antibody-dependent cellular cytotoxicity, engineered by expressing clinically targetable surface markers (e.g., EGFRopt) on CAR-T cells, thereby enabling their rapid eradication by immune effector cells when necessary. This system plays a critical role in safeguarding CAR-T therapies by promptly mitigating severe adverse effects caused by excessive immune activation or off-target toxicity, thereby significantly enhancing treatment controllability and expanding its clinical applicability.

Robust surface detection of truncated EGFR on primary human CAR-T cells. (OA Literature) Fig.1 Engineering primary human CAR-T cells with a truncated EGFR safety switch.¹

Solid Tumor Targeting CAR-T Development Service with ADCC Switch at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with ADCC Switch designs and optimizes CAR constructs to overcome the immunosuppressive TME while incorporating our EGFRopt-based ADCC switch, enabling rapid, antibody-mediated elimination using clinically available antibodies. Our approach ensures both enhanced efficacy and reliable toxicity control, translating advanced synthetic biology into clinically viable and safer cell products.

What We Can Offer

We offer a comprehensive suite of advanced engineering strategies for solid tumor-targeting CAR-T cells, integrating humanized safety switches, antibody-mediated depletion, pharmacokinetic control, and multi-layered logic-gating to enhance both efficacy and safety profiles.

Featured services of solid tumor targeting CAR-T development service with ADCC switch. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Antigen Information: Sequence, expression profile (normal vs. tumor tissue), and confirmation of target-binding domain specificity.
T Cell Source Material: Project scope and initial requirements regarding patient samples (e.g., source from leukapheresis, PBMCs) or healthy donor cells.

Key Steps:

Workflow of solid tumor targeting CAR-T development service with ADCC switch. (Creative Biolabs Original)

Final Deliverables:

Optimized CAR Construct Vector.
Comprehensive In Vitro Potency and Safety Report.

Key Advantages

Customized Vector Architecture: We provide fully tailored CAR designs, including novel single-chain variable fragment (scFv) selection, optimized co-stimulatory domains, and customized effector payload integration to meet your specific solid tumor target profile.
Superior Programmable Safety: Integration of our advanced EGFRopt ADCC safety switch variant guarantees maximum cell surface expression, enabling rapid, robust, and antibody-mediated T cell depletion for potent toxicity control, superior to first-generation switches.
TME-Overcoming Potency: Capability to engineer armed CAR T-cells to significantly enhance T-cell persistence, boost cytotoxicity, and effectively modulate the immunosuppressive TME for durable solid tumor efficacy.

FAQs

How does the ADCC switch compare to traditional suicide genes such as iCasp9?

The ADCC switch, especially in its optimized EGFRopt form, provides distinct advantages over conventional suicide systems like iCasp9. First, it enables rapid, antibody-dependent elimination via clinically available antibodies such as cetuximab, bypassing the need for small-molecule activator drugs, thereby streamlining clinical administration. Second, our engineered design ensures consistent and high-level surface expression, resulting in significantly faster and more reliable depletion kinetics than standard safety switches.

Can your CAR-T designs address complex targets, including those prone to inducing fratricide in T cell malignancies?

Indeed. We specialize in developing CAR-T vectors for challenging shared antigens, employing tailored CAR architectures and vector designs that mitigate fratricide while preserving potent antitumor efficacy. This strategy is reinforced by integrated safety mechanisms, such as the tEGFR-based safety switch, to ensure controllability in targeting such high-risk antigens.

Why Choose Us?

As experts in immuno-metabolic regulation, we deliver precision-engineered CAR-T solutions for solid tumors. Our ADCC switch technology enhances safety controllability while synthetic biology platforms ensure superior cell persistence and accelerated timelines. Partner with us to transform challenging immunosuppressive microenvironments into clinical successes with robust preclinical validation.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service in our research has significantly improved the clinical translatability of our candidate. The rapid ADCC-mediated elimination kinetics achieved with their optimized EGFR switch are far superior to the first-generation designs we previously tested, allowing us to confidently mitigate toxicity risk." Dr. J***s.

"Creative Biolabs' approach to armed CAR T design was instrumental. Their expertise in integrating IL-12 secretion addressed the TME barrier directly, resulting in sustained tumor regression in our PDX models where conventional CAR-T cells failed. The process was highly communicative and efficient." Prof. S***.

How to Contact Us?

To learn more about how our Solid Tumor Targeting CAR-T Development Service can accelerate your project and mitigate clinical risk, please reach out to our team of specialists.

Reference

Shabaneh, Tamer B et al. "Safety switch optimization enhances antibody-mediated elimination of CAR T cells." Frontiers in molecular medicine vol. 2 1026474. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fmmed.2022.1026474.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.